About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

CP-751,871 Treatment For Patients With Multiple Myeloma

NCT01536145·6 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Pfizer

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Previously treated multiple myeloma with a quantifiable serum (M spike ≥ 1 g/dL) and/or urine (≥ 200 mg/24-hr) paraprotein
Adequate bone marrow, renal, liver and cardiac function
Eastern Cooperative Oncology Group \[ECOG\] performance status less than or equal to 2

You may not be if

Prior allogeneic stem cell transplant (alloSCT)
Myelosuppressive chemotherapy or immunotherapy within 3 weeks prior to treatment with CP-751,871
Prior organ allograft
Concurrent use of insulin, oral hypoglycemic medication, growth hormone (GH), or growth hormone inhibitors
Female patients who are pregnant or lactating

The record

StatusCompleted

PhasePhase 1

Taking part47

StartedDec 2003

UpdatedMar 15, 2013

Conditions

Multiple Myeloma

Where6

Pfizer Investigational Site
Phoenix, Arizona, United States
Pfizer Investigational Site
Scottsdale, Arizona, United States
Pfizer Investigational Site
Tampa, Florida, United States

Clareo Health | CP-751,871 Treatment For Patients With Multiple Myeloma